Zenwork’s membership in NACTP will allowâ?¯Zenwork to deepen its involvement in national efforts to modernize electronic filing and data security standards, expanding access to secure, automated tax compliance solutions for tax professionals. FAYETTEVILLE, AR / ACCESS Newswire / January 8, 2026 / Zenwork, Inc., the leading provider of digital tax compliance and information-reporting solutions and […]

(CNSX:EATH.CN),(CNSX:EATH), Vancouver, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) — NEW EARTH RESOURCES CORP. (CSE: EATH) (“New Earth” or the “Company“) is pleased to outline its planned exploration program for the SL Project, a property prospective for rare earth elements (“REE”) in the Strange Lake area of Quebec, Canada. This initiative marks a strategic first

New Earth Resources Announces Comprehensive Exploration Program for its SL Rare Earth Elements Project GlobeNewswire January 08, 2026 Vancouver, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) — NEW EARTH RESOURCES CORP. (CSE: EATH) (“New Earth” or the “Company“) is pleased to outline its planned exploration program for the SL Project, a property prospective for rare

BOSTON, Mass. and ZURICH, Switzerland, Jan. 08, 2026 (GLOBE NEWSWIRE) — PathAI, a global leader in AI-powered pathology, today announced a strategic collaboration with University Hospital Zurich (USZ) to deploy AISight(R) Dx1, PathAI's CE-IVD digital pathology platform, together with AIM-TumorCellularity (AIM-TC)2 to support tumor cell content (TCC) quantification in routine molecular workflows. The collaboration marks

LONDON, Jan. 08, 2026 (GLOBE NEWSWIRE) — Engitix Ltd (“Engitix”), a biotech company targeting the extracellular matrix (ECM) to develop transformative therapies for cancer and fibrosis, today announced the closing of a $25 million Series A extension financing, by Netherton Investments, a fund investing on behalf of Mike Platt, the co-founder and Managing Director of

Leuven, Belgium. January 8, 2026. Onco3R Therapeutics, a clinical-stage immunology and oncology biotech company dedicated to transforming patients' lives with best-in-class medicines, today announced the appointment of Lawrence M. Blatt, PhD, MBA as Chair of its Board of Directors. Dr. Blatt brings substantial expertise in strategic leadership, drug development and operations together with extensive experience,

Engitix Announces $25 Million Series A Extension Financing by Existing Investor Mike Platt to Advance ECM-Targeted Therapeutics in Solid Tumors and Fibrosis Company has built one of the largest proprietary extracellular matrix (ECM) datasets spanning fibrosis and solid tumors GlobeNewswire January 08, 2026 LONDON, Jan. 08, 2026 (GLOBE NEWSWIRE) — Engitix Ltd (“Engitix”), a biotech

Onco3R Therapeutics Appoints Lawrence Blatt as Chair of the Board for Onco3R Therapeutics GlobeNewswire January 08, 2026 Leuven, Belgium. January 8, 2026. Onco3R Therapeutics, a clinical-stage immunology and oncology biotech company dedicated to transforming patients' lives with best-in-class medicines, today announced the appointment of Lawrence M. Blatt, PhD, MBA as Chair of its Board of

PathAI and University Hospital Zurich Announce Collaboration to Deploy AISight(R) Dx and AIM-TumorCellularity for Routine Molecular Pathology Workflows GlobeNewswire January 08, 2026 BOSTON, Mass. and ZURICH, Switzerland, Jan. 08, 2026 (GLOBE NEWSWIRE) — PathAI, a global leader in AI-powered pathology, today announced a strategic collaboration with University Hospital Zurich (USZ) to deploy AISight(R) Dx1, PathAI's

(TSE:4565.T), Vamorolone is approved and marketed as AGAMREE(R) for the treatment of Duchenne Muscular Dystrophy (DMD) in the US, European Union, UK and China New five-year data on vamorolone highlighted substantially improved safety profile with reduced vertebral fractures, lower incidence of cataracts and that normal growth rate was maintained. With adverse effects being a key